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Abstract
Radiation induced Lumbosacral plexophaty (RILP) is a rare but severe complication that has a considerable impact
on quality of life. Its occurrence is rare but increasing with improved long-term cancer survival. This entity
commonly results in different degrees of sensory and motor deficits. The pathophysiological mechanisms are not
yet fully understood. Diagnosis of radiation myelopathy in women with gynecologic malignancies may increase
with the use of concomitant chemo-radiation. This report describes the effect of this combination therapy in a
64-year-old woman with cervical carcinoma.
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Background
Cancer patients are surviving for many years and so the
management of late treatment related complications that
reduce their quality of life has become a public health
priority [1].
One of the complications associated with pelvic radiation
that is extremely rare but, at the same time, provides many
diagnostic and even more therapeutic problems is radi-
ation- induced lumbosacral plexopathy (RILP) [1, 2]. It is a
chronic handicap, frightening because progressive and usu-
ally irreversible, usually appearing several years after radio-
therapy [1]; diagnosis is by exclusion and the treatment
remains a matter of development thanks to the better un-
derstanding of its pathophysiology. Its occurrence is rare
but increasing with improved long-term cancer survival.
We present a case of cervical cancer patient success-
fully treated, who developed nine years after, serious
radiotherapy-induced complications in the form of lum-
bosacral plexopathy.
Case Report
A 64-year-old woman, G16 P12, was admitted in December
2004, with an 8-month history of pelvic pain associated
with minimal post coital bleeding, his Medical history was
unremarkable. Examination was significant for a 3 cm, exo-
phytic cervical lesion; biopsies confirmed a differentiated
squamous cell carcinoma. Patient preferred to have a rad-
ical hysterectomy. Surgical staging revealed a 6 cm of differ-
entiated squamous cell cervical carcinoma with proximal
left parametrial invasion, but no significant adenopathy,
compatible with stage IIB.
Following tumour board discussion the patient was
scheduled to receive external radiation to the pelvis
followed by brachytherapy to the tumor mass. Along
with radiation, the patient was planned to receive
Cisplatin, at the dose of 40 mg per square meters per
week (mg/m2/week).
In the period from 4 February 2005 to 16 March 2005,
radiotherapy was delivered with once daily treatment at
2 Gy per fraction per day, five fractions per week. The
overall schema is to the small pelvis for 23 fractions to
46 Gy.
Linear accelerators with beam energy of 25 MV were
used. The small pelvis field included an anteroposterior/
posteroanterior fields to encompass 3 to 4 cm of the vaginal
cuff, the parametria, the entirety of the external iliac, internal
iliac, and obturator nodal basins. The field borders were as
follows: superior at the L4-L5 interspace, laterally 1.5 cm be-
yond the bony pelvis, and inferior at the obturator foramen.
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Concurrent with radiation, five courses of Cisplatin (40 mg/
m2/week) were administered; the treatment was tolerated
well with decrease in pelvic pain, a urinary tract infection
treated with oral antibiotics, and intermittent diarrhea.
Six weeks following the completion of radiation, an add-
itional 15 Gy were administered with LDR brachytherapy
using a vaginal cylinder applicator loading with Iridium
192 source, the dose is delivered at 0.25 to 1 Gy/h per
daily fraction. The total dose treatment was 61 Gy and the
total duration was approximately 13 weeks.
Follow-up examination included bimanual examin-
ation every 3 months for 2 years, with abdominal and
pelvic CT when indicated, every 6 months for 3 more
years and yearly thereafter.
Nine years after completion of treatment, the patient was
readmitted due to progressive, bilateral leg pain and lower
extremity weakness, greater on the left side, leaving her un-
able to walk, with sensory changes over the lateral legs and
feet, her bladder and rectal functions remained intact.
Physical exam was significant for considerable remission
of the central tumor with some radiation changes in the
vaginal part. Neurologic exam found a bilateral lower ex-
tremity weakness greater on the left side, with decreased
motor function in hip and knee flexion, weakening of pain
and touch sensations in respect to L5, S1 roots.
Diagnostic studies including an abdominal-pelvic CT
scan showed complete resolution of the primary tumor
with no evidence of loco-regional recurrence. Cervical
cytology was negative. Bilateral leg Doppler studies were
normal. Magnetic resonance imaging (MRI) of the thor-
acic and lumbosacral spine did not show any patholo-
gies, the T2 weighted MRI images revealed only increase
in signal intensity in the radiated segment of cord sug-
gestive of reactive lesion (Figs. 1, 2 and 3).
Mobility problems and pain in the lumbosacral spine
were slowly but steadily growing, the patient was treated
with oral morphine, gabapentin and Vitamins B1–B6.
Electromyogram and nerve conduction studies revealed
a bilateral abnormality consistent with L4, L5, S1, radicu-
lopathy greater on the left side. Cerebrospinal fluid (CSF)
analyses were negative with no evidence of malig-
nancy, infectious, or inflammatory process. Complete
blood count and serum chemistry showed no abnor-
mality that explained her syndrome. Finally the diag-
nosis of radiation-induced lumbosacral plexopathy
was made by exclusion.
Five months post-treatment the patient’s symptoms
have stabilized without significant improvement in her
lower extremity weakness, at the time of this report, she
Fig. 1 Spinal cord MRI T1-weighted sequence
Fig. 2 Spinal MRI T2-weighted sequence
Fig. 3 Spinal MRI T2-weighted sequence
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has improved 50 % of her subjective baseline and can
now walk with crutches. She remains on gabapentin.
Discussion
For a number of years, radio-chemotherapy has been a
treatment of choice in cervical cancer patients, starting
from stage IB2 [2]. Radiation induced Lumbosacral plex-
ophaty (RILP) is a rare but severe complication; its
frequency ranges from 0.3 % to 1.3 % [2, 3]; it is charac-
terized by a latent period between radiation exposure
and the development of symptoms, according to data
from the literature, it may take even 30 years from the
end of radiotherapy to occurrence of neurological symp-
toms [2, 4–6].
Predisposing factors and the exact mechanism have
been not be clearly elucidated, but factors that can lower
the spinal cord tolerance to ionizing radiation include ad-
vanced age, obesity, hypertension, diabetes, dyslipidemia
[6–8]. In addition to factors related to radiotherapy treat-
ment such as a large total dose (>50 Gy to plexus, >60 Gy
to cranial nerves) [1, 5, 6, 8–10], large dose per frac-
tion [1, 5, 6, 9, 11], heterogeneous high-dose distribu-
tion [12], hot spot high dose (field junctions) [1, 13],
intracavitary radium source [1, 13].
Recently, it has been suggested that the use of combined
treatment might also lower the spinal cord tolerance to
radiotherapy [1, 2, 6, 8]. In this present case, the proposed
ballistic included only an anteroposterior/posteroanterior
fields to 46 Gy, leaving the plexus inside all the time, with
an additional 15 Gy of brachytherapy. Unfortunately the
dose that the lumbosacral plexus received has not been
determined.
On the other hand, some authors [1, 2, 6, 8] draws at-
tention to the use of cisplatin in the treatment of cervical
cancer with known secondary peripheral neurotoxicity,
our patient received five courses of cisplatin; therefore, it
remains to be determined whether the concomitant use of
cisplatin with radiation will result in an increase in this
neurological complication in our case.
RILP pathogenesis has been highly debated; nerve
compression by indirect extensive radiation-induced fi-
brosis plays a central role; Schultheiss et al. [14, 15] sug-
gest that injury to blood vessels especially venous by
ischemia following capillary network failure remains the
critical event.
Delanian et al. [1] defined this complication as a dy-
namic process related to perturbations at various levels
of physiological homeostasis, characterised by gradual
stepwise worsening over a period of several years, with
the early changes consisting of spongy demyelination
and axonal swelling, followed by atrophy, vascular dam-
age, and plasma cell infiltrate in the latter stages.
Usually the symptoms begins with moderate pelvic
pain (50 % of patients) [5, 9], the onset of neurological
signs is insidious, with damage that is largely motor in
the form of strong, persistent pain and reduced muscu-
lar strength, this symptoms are usually bilateral and asy-
metric with initial unilateral damage [1, 5, 9, 16]; the
sensory signs and paraesthesia are absent or noted very
late [1, 5]. Our case correspond to this clinical presenta-
tion, as well the first neurological symptoms, manifesting
as progressive bilateral leg pain and lower extremity
weakness, greater on the left side, with sensory changes
over the lateral legs and feet.
Lumber magnetic resonance imaging (MRI) represents
the first line exam; it does not play a determinant role in a
positive diagnosis, but does eliminate tumour invasion or
lumbar canal stenosis [8, 15]. Cerebrospinal fluid (CSF)
evaluations may detect an elevated CSF protein; however,
CSF is often negative for malignant cells, infection, or evi-
dence of multiple sclerosis [6, 8, 15].
The diagnosis of RILP is essentially one of exclusion,
metastasis or a local tumor progression with secondary
nerve involvement usually leads the differential diagnosis,
the minimal workup must include cerebrospinal fluid ana-
lysis, electromyography, and CT or MRI scans of the
spinal cord [6, 8].
In all, three criteria have been proposed to retain the
diagnosis of RILP: a history of radiotherapy in which the
spinal cord was included within the field of radiotherapy,
the main neurologic lesion is within the segments of the
cord exposed to radiotherapy, and metastatic and other
primary spinal cord diseases have been ruled out [6, 15].
No effective treatment for RILP exists; it has been
known that combined pentoxifyllin-tocopherol (PE) sig-
nificantly reduces symptoms due to their synergistic
clinical and biological properties [17, 18]. Recently,
Clodronate (a bisphosphonate, inhibits osteoclastic bone
destruction with anti-inflammatory effects, and inhibits
macrophagic myelin nerve destruction in rats [19]) when
combined with pentoxifylline-tocopherol (PENTOCLO),
healed 54 patients with refractory osteoradionecrosis in a
median of 9 months [20]. Moreover, neurological symp-
toms were reduced by half in two patients with progres-
sive RILP after 3 years of PENTOCLO treatment, results
that have led to an ongoing phase III randomised clinical
trial in France (NCT01291433) [1].
Symptomatic treatment includes conventional analge-
sics for pain, benzodiazepines for paraesthesia, quinine for
cramps and membrane-stabilising drugs (carbamazepine)
for reducing nerve hyperexcitability. Vitamins B1–B6 are
often used routinely, but detailed data are lacking. Physical
therapy is valuable in maintaining function and preventing
joint complications [1, 2, 6, 8, 15].
In today’s clinical practice, the best approach is always pre-
vention in respect of radiotherapy limits by reducing total
dose, dose per fraction and volume every time if possible,
while identifying patients with serious comorbidities [1, 15].
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Conclusion
RILP is a rare but devastating complication that has a
considerable impact on quality of life in patients consid-
ered to be cured of their cervical cancer, Improved un-
derstanding and earlier diagnosis of this complication,
before the lesions become progressive and irreversible, is
particularly important, and more surveillance will be
needed to assess the true incidence of this rare compli-
cation, its evolution and the best treatment to relieve it.
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